BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Company News  |  Deals

Ipsen, Roche deal

Roche said it will return taspoglutide to Ipsen. Roche had rights under a 2003 deal to the long acting glucagon-like peptide-1 (GLP-1) analog, which was in Phase III testing to...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >